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An outbreak of viral encephalitis occurred in
Gorakhpur, India, from July through November 2005. The
etiologic agent was confirmed to be Japanese encephalitis
virus by analyzing 326 acute-phase clinical specimens for
virus-specific antibodies and viral RNA and by virus isola-
tion. Phylogenetic analysis showed that these isolates
belonged to genogroup 3.
A
n epidemic of viral encephalitis was reported from
July through November 2005 in Gorakhpur, Uttar
Pradesh, India. It was the longest and most severe epidem-
ic in 3 decades; 5,737 persons were affected in 7 districts
of eastern Uttar Pradesh, and 1,344 persons died (1).
Japanese encephalitis virus (JEV) is the most common
cause of childhood viral encephalitis in the world; it caus-
es an estimated 50,000 cases and 10,000 deaths annually
(2,3). JEV is endemic in the Gorakhpur and Basti divisions
of eastern Uttar Pradesh. The geographic features of this
region are conducive for the spread of JEV; an abundance
of rice fields and a bowl-shaped landscape allow water to
collect in pools. Heavy rains saturated the ground in 2005,
which caused ideal breeding conditions for mosquitoes
that transmit the virus from pigs to humans. In addition,
high temperature and relative humidity provided a suitable
environment for JEV transmission.
We report in-depth investigations of JEV-specific anti-
bodies, virus isolation, and demonstration of viral RNA in
326 febrile patients with encephalitis symptoms who were
admitted to B.R.D. Medical College, Gorakhpur. Further
molecular epidemiologic studies were performed to estab-
lish the genetic relatedness of the viral strain associated
with this epidemic.
The Study
Atotal of 326 clinical samples (185 blood and 141 cere-
brospinal fluid [CSF]) were collected from the 326 patients
who had a diagnosis of encephalitis. Two sets of blood
samples, with and without anticoagulant, were collected
for virus isolation and serologic tests. All serum and CSF
samples were screened for JEV-specific immunoglobulin
M (IgM) and IgG by using an in-house dipstick ELISAthat
incorporated nitrocellulose as the solid phase. Purified
viral antigen was obtained from culture supernatant of
infected C6/36 cultures by sucrose density gradient ultra
centrifugation (4–6). Results were confirmed by using an
in-house IgM capture ELISA (7).
JE-specific RNA was detected by using the Access
quick one-step reverse transcription (RT)–PCR kit
(Promega, Madison, WI, USA) with the primer pairs
JED3S: ATG CGC GGATCC GAC AAACTG GCC CTG
AA(1839–1867) and JED3C: GGG GAAGCT TCG TGC
TTC CAG CTT TGT CC (2193–2165) on the basis of the
sequence in domain III of the E gene of strain JaOArS982
(8).
Virus isolation was attempted in C6/36 cells (4) from RT-
PCR– and IgM-positive serum and CSF samples according
to standard protocol (5). Double-stranded sequencing of
domain III of the E gene of JEV was performed on an ABI
310 sequencer (Applied Biosystems, Foster City, CA,
USA) with the BigDye Terminator cycle sequencing ready
reaction kit. The phylogenetic tree was constructed with
the neighbor-joining method with bootstrap analysis of
1,000 replicates with the MEGA version 2.1 program (9).
Rural populations between the ages of 3 months and 15
years were affected; almost 50% of children 6–10 years of
age were affected, and 35% of children <5 years of age
were affected. The epidemic affected boys and girls at a
ratio of 1.9 to 1. The overall case-fatality ratio was 23%.
Children dominated the case load because most adults in
the area are immune to the virus. The trend of the epidem-
ic showed that most cases were reported from the first to
third weeks of October. Clinical history showed that all
patients had fever (temperatures 38.5°C–40°C); prominent
symptoms included severe headache, convulsions, and
vomiting, leading to paralysis, coma, and death.
Analysis indicated an overall positivity of 50% of
serum samples and 30% of CSF samples. The antibody
profile of the serum samples showed 23% IgM, 19% IgG,
and 7% both IgM and IgG positivity, compared with 26%
IgM, 4% IgG, and 1% both IgM and IgG positivity in CSF
samples. A total of 9% of CSF samples were positive for
JEV-specific RNA (355-bp amplicon) as determined by
RT-PCR. All these RT-PCR–positive CSF samples were
also positive for IgM. None of the serum samples were
positive by RT-PCR for viral RNA. Adding RT-PCR– and
IgM-positive samples to C6/36 cells yielded 7 JEV isolates
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ELISAand RT-PCR. The antibody profile of the RT-PCR–
and isolation-positive samples is depicted in Table 1.
Further analysis of a 355-nucleotide sequence in
domain III of the E gene of these isolates showed >95%
homology with JEV on BLAST search. On comparison
with 24 other geographically diverse JEV isolates
(Table 2), all JEV isolates sequenced in this study were
closely related (>99% homology). The isolates from this
outbreak showed a nucleotide sequence identity of 95.6%
and 94.6% with prototype JEV (Nakayama strain) and the
first Indian JEV (isolated from Vellore in 1956), respec-
tively. The dendrogram showed that the JEV isolates
responsible for the 2005 Gorakhpur epidemic belong to
genogroup 3 (G3) but form a cluster separate from earlier
Indian isolates (Figure).
Conclusions
The Gorakhpur district of Uttar Pradesh, which shares
a border with Nepal and Bihar, has been experiencing peri-
odic outbreaks of JEV since 1978. The virus cannot usual-
ly be isolated from clinical specimens, even with the best
laboratory facilities, probably because of low levels of
viremia and the rapid development of neutralizing antibod-
ies. The diagnosis is therefore usually based on the pres-
ence of antibodies. The IgM capture ELISA for serum and
CSF has become the accepted standard for diagnosing
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The presence of only IgG antibodies in 19% of the
patients indicated exposure to JEV infection in the past.
This finding was expected because JEV is endemic to
northern India, particularly Gorakhpur, and several large
JEV epidemics have occurred in the past decade. In the
present study, only 13 CSF samples (9%) were positive by
RT-PCR. Seven virus isolates were obtained from IgM-
positive CSF samples that did not yield RT-PCR amplicons
before cultivation. Similar variations in virus detection and
isolation have been reported (10,11); these findings under-
score the sensitivity of cell culture systems for amplifica-
tion of viable virus. Furthermore, the inability to detect
genomic RNA or isolate virus from serum samples was
striking and highlights the need for CSF sampling for both
clinical diagnosis and epidemiologic studies.
We also investigated the molecular epidemiology of the
outbreak by comparative sequence analysis of the isolates
obtained in this study with reference strains of JEV.
Domain III of the E gene was targeted for this purpose
because this is the region under immune selective pressure,
and it exhibits sufficiently rapid mutation to show evolu-
tionary and epidemiologic relationships (12–14). We deter-
mined the partial sequence of these isolates directly from
clinical samples without risk of altering the genome by
passage in vitro. The dendrogram showed that the G3 of
JEV is still circulating in India. However, compared with
isolates from 1956 to 1988, recent isolates form a separate
cluster. Frequent introduction of new virus genotypes
through bird migration has led to shifts in circulating geno-
types in neighboring Asian countries, including Japan,
Vietnam, China, Korea, Sri Lanka, and Malaysia (3,15).
Therefore, detailed and continuous epidemiologic surveil-
lance is warranted to monitor the incursion and spread of
JEV genotypes in India, which will allow effective control
and management strategies to be undertaken at the earliest
opportunity.
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